Ocular Proteomics Testing In Chronic Atrophy

Who May Qualify: - Male or female subjects aged between 50 and 89 years, inclusive - For the GA cohort: Clinical diagnosis of GA secondary to AMD or dAMD in the study eye, confirmed by fundus autofluorescence imaging and spectral-domain optical coherence tomography (SD-OCT). - For the control cohort: No clinical evidence of retinal disease in either eye. - Best-corrected visual acuity (BCVA) of ≥20/200 in the study eye, as measured by Early Treatment Diabetic Retinopathy Study (ETDRS) charts - Ability and willingness to provide written willing to sign a consent form before any study-specific procedures. Who Should NOT Join This Trial: - Presence of active ocular infection or inflammation in either eye at the time of screening. - History of intraocular surgery in the study eye within the three months preceding enrollment. - Intraocular pressure (IOP) greater than 21 mmHg in the study eye at screening - Use of systemic anticoagulation therapy that cannot be safely discontinued prior to ACP. - Pregnant or nursing women. - Known hypersensitivity or contraindication to any of the medications or procedures used in the study. Always talk to your doctor about whether this trial is right for you.